NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM

NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Sponsor

Arcus Biosciences, Inc

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT04772989

Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

First Posted : February 26, 2021

Click here to see details on ClinicalTrials.gov

---

Drug: AB308

Anti-TIGIT Monoclonal Antibody AB308

Anti-TIGIT Monoclonal Antibody AB308 (Code C179552)

AB 308

AB-308

AB308

Anti-TIGIT Monoclonal Antibody AB308

---

Drug: Zimberelimab, AB122

Zimberelimab

Zimberelimab (Code C159549)

AB 122

AB-122

AB122

Anti-PD-1 Monoclonal Antibody GLS-010

GLS 010

GLS-010

GLS010

WBP-3055

Zimberelimab

ZIMBERELIMAB

---

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Florida

United States, Georgia

United States, Indiana

United States, Iowa

United States, Kentucky

United States, Michigan

United States, Minnesota

United States, New York

United States, Ohio

United States, Oklahoma

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Utah

United States, Virginia

United States, Wisconsin